Evidence map›Paper›PMID 28924109›Full record

ArticleInternal medicine (Tokyo, Japan)2017

Retroperitoneal Bulky Histiocytic Sarcoma Successfully Treated with Induction Chemotherapy Followed by Curative Surgery.

Masafumi Oto, Akiko Maeda, Taku Nose, Yujiro Ueda, Shima Uneda, Akito Inadome, Koichi Oshima, Minoru Yoshida

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Histiocytic Sarcoma: A Review and Update.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Masafumi OtoDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Japan.
Akiko MaedaDepartment of General Internal Medicine, Japanese Red Cross Kumamoto Hospital, Japan.
Taku NoseDepartment of General Internal Medicine, Japanese Red Cross Kumamoto Hospital, Japan.
Yujiro UedaDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Japan.
Shima UnedaDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Japan.
Akito InadomeDepartment of Urology, Japanese Red Cross Kumamoto Hospital, Japan.
Koichi OshimaDepartment of Pathology, Kurume University, Japan.
Minoru YoshidaDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Japan.
Japanese Red Cross Kumamoto Hospital · JPKurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histiocytic sarcoma (HS) is a rare hematopoietic neoplasm. We report a patient with HS treated with induction chemotherapy followed by curative surgery. A 50-year-old man was referred to our hospital because of a retroperitoneal tumor. A computed tomography scan revealed a bulky retroperitoneal mass, infiltrating the surrounding organ. An excisional biopsy confirmed the diagnosis of HS. The tumor shrunk after multidrug chemotherapy. However, positron emission tomography showed uptake of fludeoxyglucose in the residual tumor. He underwent right nephrectomy to remove the tumor. Pathological examination showed complete response. Surgery combined with induction chemotherapy may be an effective way to manage HS.

Indexed as

BiopsyFluorodeoxyglucose F18Histiocytic SarcomaHumansInduction ChemotherapyMaleMiddle AgedPositron-Emission TomographyRemission InductionRetroperitoneal NeoplasmsTomography, X-Ray ComputedFluorodeoxyglucose F18chemotherapyhistiocytic sarcomasurgery

Identifiers

PMID28924109
PMCPMC5675940
OpenAlexW2755749657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.